本帖最后由 老马 于 2013-3-13 13:43 编辑 . |, q8 L) N, ^
8 |7 @4 E! b+ B" v& O7 y
健择(吉西他滨)+顺铂+阿瓦斯汀
- ^' U. k# S% k8 C1 q Gemzar +Cisplatin + Avastin
( Z& r( b+ ~, K! u# n. v% ihttp://annonc.oxfordjournals.org/content/21/9/1804.full) \6 }6 O4 L8 U5 X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ u# u3 M% x% l/ H }- G+ e/ _Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& e: L8 a3 `: J, O3 x6 T) v7 NResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 8 P0 l3 G. b% ]& b7 G, }
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1025)
# v# a: D! A5 ~8 t华为网盘附件:
?$ I& a, U" x4 {4 ]【华为网盘】ava.JPG
y0 \, w- F6 {* d4 n' s) f |